NextGen Bio
Filter News
Found 7,320 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Epic Bio to Present Preclinical Data at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
5/4/2023
Epic BIO announced the acceptance of an abstract for oral presentation at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy taking place May 16-20, 2023, in Los Angeles, Calif.
-
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
5/4/2023
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics , Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.
-
Visus Therapeutics Announces New Scientific Data to Be Presented During the 2023 ARVO Annual Meeting
4/19/2023
Visus Therapeutics Announces New Scientific Data to Be Presented During the 2023 ARVO Annual Meeting.
-
Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023
4/17/2023
Strand Therapeutics announced today preclinical data from its programmable mRNA therapy STX-001, a multi-modal synthetic self-replicating mRNA technology that delivers a prolonged and locally-acting IL-12 cytokine to the tumor microenvironment.
-
Visus Therapeutics Appoints Ophthalmology Industry Expert Jehan Tamboowalla to Senior Vice President of Business Development and Marketing
4/12/2023
Visus Therapeutics Inc. today announced Jehan Tamboowalla joined the company as senior vice president of business development and marketing.
-
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
3/27/2023
ArriVent Biopharma, Inc. today announced the completion of a $155 million oversubscribed Series B financing.
-
Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia
3/22/2023
Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL ™ PF for the Treatment of Presbyopia.
-
Backed by Google Ventures, ARCH Venture Partners and more, Chroma Medicine announced the closing of a $135 million Series B financing Wednesday. -
Strand Therapeutics Appoints Jay Stella as Chief Business Officer
3/1/2023
Strand Therapeutics today announced the appointment of Jay Stella, MBA as Chief Business Officer.
-
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines
3/1/2023
Chroma Medicine, Inc. announced the completion of a $135 million Series B financing led by GV, with participation from additional new investors ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, and all existing investors, including Alexandria Venture Investments, Atlas Venture, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, and Wellington Management.
-
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
2/21/2023
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full year 2022 financial results after the Nasdaq Global Market closes on Tuesday, February 28, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2022 financial results and to provide a corporate update.
-
Enveda's primary R&D efforts will focus on inflammation, fibrosis and neurosensory biology within the GI, dermatology and pulmonary therapeutic areas. -
Curie.Bio launched this week with $520 million to take early startups from ground zero through Series A funding. -
Visus Therapeutics Appoints World-Renowned Ophthalmologist, Eric D. Donnenfeld, M.D., to Board of Directors
1/11/2023
Visus Therapeutics Inc. today announced the appointment of Eric D. Donnenfeld, M.D., to the Company’s Board of Directors.
-
Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer
1/6/2023
Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced the appointment of Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer.
-
Simnova and Orna Therapeutics Collaborate to Advance Orna's Next Generation Circular RNA Technology in China
1/5/2023
Shanghai Xianbo Biotech Co., Ltd. and BiTE-armed CAR-T cell therapies, and Orna Therapeutics today announced a collaboration agreement to discover, develop, and commercialize multiple potential therapeutics in the area of oncology.
-
LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
1/5/2023
LEXEO Therapeutics, Inc. today announced the expansion of its leadership team, with the appointment of Micah Zajic as Chief Financial Officer and Paula H.J. Cholmondeley to its Board of Directors as Audit Committee Chair.
-
Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
1/5/2023
Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the close of a Series B extension financing, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors.